State of the art in muscle glycogenoses

C. Angelini

Research output: Contribution to journalArticlepeer-review


The recognition of a series of metabolic/enzymatic dysfunctions in glycogenoses has allowed new therapeutic advances for their treatment due to the development of recombinant enzyme. A recent advance appears enzymatic replacement therapy (ERT) in glycogenosis type II in both infantile, juvenile and adult form. Targeted manipulation of diet has been tried both in glycogenosis type II (Pompe disease) and type V (Mc Ardle disease).

Original languageEnglish
Pages (from-to)339-342
Number of pages4
JournalActa Myologica
Issue numberOCTOBER
Publication statusPublished - Oct 2010


  • Enzyme replacement therapy
  • Glycogenosis
  • McArdle disease
  • Pompe disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'State of the art in muscle glycogenoses'. Together they form a unique fingerprint.

Cite this